Protein Binding of Macromolecular Anticancer Agent SMANCS: Characterization of Poly(styrene-co-maleic acid) Derivatives as an Albumin Binding Ligand

Journal of Bioactive and Compatible Polymers - Tập 3 Số 4 - Trang 319-333 - 1988
Akira Kobayashi1, Tatsuya Oda1, Hiroshi Maeda1
1Department of Microbiology, Kumamoto University Medical School, Kumamoto 860, Japan

Tóm tắt

We have studied the interaction of macromolecular anticancer agent SMANCS, a conjugate of partially half-butyl-esterified styrene-co-maleic acid polymer[butyl-SMA]- and neocarzinostatin (NCS), with various serum proteins by the fluorescence polarization method. Comparatively strong binding of FITC-labeled SMANCS (F-SMANCS) to human serum albumin (HSA) and weak binding to fibrinogen were observed, while other serum proteins did not exhibit any appreciable binding profile. From Scatchard polt analysis, the asso ciation constant of binding for F-SMANCS to HSA at 37 °C, pH 7.4 was calculated to be 2.19 × 106 M-1 and the number of moles of F-SMANCS bound to 1 mol of HSA was 3.2 Binding of F-NCS to HSA was not observed. The F-SMANCS bound to HSA was effectively displaced by butyl-SMA, but not by NCS. This evidence supports that SMANCS binds to HSA through butyl-SMA, not through NCS portion. A role of the alkyl ester groups of SMA derivatives to HSA binding was investigated by competitive inhibition using butyl-SMA, ethyl-SMA, H-SMA and short chain butyl-SMA. The degree of competitive in hibition was stronger in the following order: butyl-(n = 6) > ethyl (n = 6) = short butyl-(n = 4) > H-SMA. The number of carbons introduced by esterification and the hydrophobicity of SMA derivatives both positively in fluence the binding affinity to HSA. The binding site for SMANCS on HSA was investigated. From the competitive inhibition of known standard drugs (war farin, diazepam and digitoxin) and endogenous substance (bilirubin) in the albumin binding. The binding site on HSA appears to be in the close vicinity to the warfarin or diazepam binding site, and might partially overlap with the bilirubin binding site. These data support that the prolonged plasma half-life of SMANCS in vivo reported previously can be attributed to this albumin binding.

Từ khóa


Tài liệu tham khảo

10.1111/j.1399-3011.1979.tb01730.x

10.1007/BF01040499

10.1021/jm00382a012

Takeshita, J., 1982, Gann, 73, 278

Matsumura, Y., 1986, Cancer Res., 46, 6387

Oda, T., 1987, Cancer Res., 47, 3206

Oda, T., 1987, J. Nat. Cancer Inst., 79, 1205

1974, J. Adv. Cancer Res., 19, 331, 10.1016/S0065-230X(08)60058-5

Folkman, J., 1975, Biochim. Biophys. Acta., 417, 211

10.1021/bi00341a030

10.1177/000331976701800201

10.1126/science.6823562

10.1126/science.3975602

Peterson, I.I., 1973, Bibl. Anat., 12, 511

Matsumura, Y., 1986, Microcirculation Annual, 95

Maeda, H., 1988, J. Biol. Chem.

Iwai, K., 1986, Cancer Res., 44, 2115

Maeda, H., Y. Matsumura, T. Oda and K. Sasamoto. Protein Tailoring for Food and Medical Uses. R. E. Feeney and J. R. Whitaker, eds. Marcel Dekker Inc., pp. 353-382 (1986).

Maeda, H., 1988, J. Bioactive Compatible Polymer

10.1016/0003-2697(79)90649-3

10.1093/clinchem/24.12.2139

10.1021/bi00532a022

10.1093/oxfordjournals.jbchem.a135221

10.1093/oxfordjournals.jbchem.a121892

10.1093/oxfordjournals.jbchem.a129077

10.1016/S0021-9258(18)95981-8

10.1016/S0076-6879(72)25042-X

10.1021/bi00562a025

10.1002/cpt1977225part1539

10.1016/0006-2952(75)90434-7

Piafsly, K.M., 1977, Clin. Pharmacol. Ther., 22, 546

10.1021/ja01092a040

10.1111/j.1749-6632.1973.tb20491.x

Chignell, C., 1970, Pharmacol., 6, 1

10.1002/jps.2600651127

10.1002/jps.2600600207

Sjöholm, I., 1979, Mol. Pharmacol., 16, 767

10.1248/cpb.32.2414

Hansen, U.K., 1981, Pharmacol. Rev., 33, 19

10.1016/B978-0-12-568401-9.50010-4

Thông tin
Thông tin xuất bản

Journal of Bioactive and Compatible Polymers

Tập 3 Số 4

319-333

Thông tin tác giả